Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) has appointed Professor Dimitrios Trafalis, MD, as Head of Oncology at its Research and Development division. Professor Trafalis, currently serving at the National and Kapodistrian University of Athens, brings expertise in oncology-hematology, cancer cytogenetics, and personalized cancer therapies. He will lead research initiatives focusing on preclinical and clinical development strategies, regulatory support, and cutting-edge oncology studies.
As a specialist in biosciences, cancer research, and drug development, Professor Trafalis has authored multiple scientific publications and received numerous citations and international research grants. In his new role, he will oversee preclinical and clinical protocols while presenting key developments at global medical conferences and in scientific journals.
Cosmos Health (NASDAQ:COSM) ha nominato il Professor Dimitrios Trafalis, MD, come Capo di Oncologia nella sua divisione Ricerca e Sviluppo. Il Professor Trafalis, attualmente in servizio presso l’Università Nazionale e Kapodistriana di Atene, porta con sé competenze in oncologia-ematologia, citogenetica oncologica e terapie personalizzate contro il cancro. Dirigerà iniziative di ricerca focalizzate su strategie di sviluppo preclinico e clinico, supporto normativo e studi oncologici all’avanguardia.
Specialista in bioscienze, ricerca sul cancro e sviluppo di farmaci, il Professor Trafalis ha scritto numerose pubblicazioni scientifiche e ricevuto innumerevoli citazioni e finanziamenti internazionali per la ricerca. Nel suo nuovo ruolo, supervisionerà i protocolli preclinici e clinici mentre presenterà importanti sviluppi in conferenze mediche globali e su riviste scientifiche.
Cosmos Health (NASDAQ:COSM) ha designado al Profesor Dimitrios Trafalis, MD, como Jefe de Oncología en su división de Investigación y Desarrollo. El Profesor Trafalis, quien actualmente se desempeña en la Universidad Nacional y Kapodistriana de Atenas, aporta experiencia en oncología-hematología, citogenética del cáncer y terapias personalizadas para el cáncer. Liderará iniciativas de investigación centradas en estrategias de desarrollo preclínico y clínico, apoyo regulatorio y estudios oncológicos de vanguardia.
Como especialista en biosiencias, investigación del cáncer y desarrollo de medicamentos, el Profesor Trafalis ha escrito múltiples publicaciones científicas y ha recibido numerosas citas y becas de investigación internacionales. En su nuevo puesto, supervisará los protocolos preclínicos y clínicos mientras presenta desarrollos clave en conferencias médicas globales y en revistas científicas.
코스모스 헬스 (NASDAQ:COSM)가 연구 개발 부서의 종양학 책임자로 디미트리오스 트라팔리스 교수(MD)를 임명했습니다. 현재 아테네 국립 카포디스트리안 대학에서 재직 중인 트라팔리스 교수는 종양학-혈액학, 암 세포유전학 및 개인 맞춤형 암 치료에 대한 전문성을 보유하고 있습니다. 그는 전임상 및 임상 개발 전략, 규제 지원 및 최첨단 종양학 연구에 중점을 둔 연구 이니셔티브를 이끌 것입니다.
생명과학, 암 연구 및 약물 개발의 전문가인 트라팔리스 교수는 다수의 과학적 출판물을 저술했으며 수많은 인용과 국제 연구 보조금을 받았습니다. 그는 새로운 역할에서 전임상 및 임상 프로토콜을 감독하고 글로벌 의학 회의 및 과학 저널에 주요 개발 사항을 발표할 것입니다.
Cosmos Health (NASDAQ:COSM) a nommé le professeur Dimitrios Trafalis, MD, responsable de l’oncologie dans sa division Recherche et Développement. Le professeur Trafalis, qui occupe actuellement un poste à l’Université nationale et Kapodistrienne d’Athènes, apporte son expertise en oncologie-hématologie, en cytogénétique du cancer et en thérapies personnalisées contre le cancer. Il dirigera des initiatives de recherche axées sur les stratégies de développement préclinique et clinique, le soutien réglementaire et des études oncologiques à la pointe.
En tant que spécialiste des biosciences, de la recherche sur le cancer et du développement de médicaments, le professeur Trafalis a publié de nombreux articles scientifiques et a reçu de nombreuses citations et bourses de recherche internationales. Dans son nouveau rôle, il supervisera les protocoles précliniques et cliniques tout en présentant des avancées clés lors de conférences médicales internationales et dans des revues scientifiques.
Cosmos Health (NASDAQ:COSM) hat Professor Dimitrios Trafalis, MD, zum Leiter der Onkologie in seiner Forschungs- und Entwicklungsabteilung ernannt. Professor Trafalis, der derzeit an der Nationalen und Kapodistrianischen Universität Athen tätig ist, bringt Expertise in Onkologie-Hämatologie, Krebszytogenetik und personalisierten Krebstherapien mit. Er wird Forschungsinitiativen leiten, die sich auf präklinische und klinische Entwicklungsstrategien, regulatorische Unterstützung und fortschrittliche onkologische Studien konzentrieren.
Als Spezialist für Biowissenschaften, Krebsforschung und Arzneimittelentwicklung hat Professor Trafalis mehrere wissenschaftliche Veröffentlichungen verfasst und zahlreiche Zitationen sowie internationale Forschungsstipendien erhalten. In seiner neuen Rolle wird er die präklinischen und klinischen Protokolle überwachen und wichtige Entwicklungen auf globalen medizinischen Konferenzen und in wissenschaftlichen Fachzeitschriften präsentieren.
Positive
- Strategic appointment of a highly qualified oncology expert strengthens R&D capabilities
- Enhancement of the company’s oncology research pipeline and development capabilities
- Potential advancement in clinical development strategies and therapeutic solutions
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company’s Research and Development division.
Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.
He is a medical specialist in oncology-hematology, cancer cytogenetics, personalized cancer therapies, and clinical pharmacology, as well as an expert in biosciences, cancer research, drug design and development, and pharmacological innovations. He has authored multiple scientific publications in high-impact journals and received numerous citations for his work, focusing fully on experimental and clinical pharmacology and significantly advancing medical education and research in oncology and pharmacology. He has received several distinctions and grants from international research programs for his work. He holds degrees in Biology and Medicine, along with advanced postgraduate training.
This strategic engagement aligns with Cosmos Health’s commitment to advancing groundbreaking therapeutics in oncology.
Professor Trafalis will lead research initiatives focusing on the design and execution of preclinical and clinical development strategies, regulatory support, and cutting-edge studies aimed at addressing critical oncology challenges. Specifically, his role includes overseeing preclinical and clinical protocols, making strategic decisions in research, and presenting key developments at global medical conferences and in international scientific journals.
Professor Trafalis stated: “I am excited to join Cosmos Health in its mission to advance oncology research and deliver life-changing treatments to patients worldwide, and I have great expectations for a high-performance collaboration. I truly believe that the project of Cosmos Health could serve the purpose of curing individuals with cancer in advanced stages. Together, we will focus on pioneering clinical strategies that address some of the most pressing challenges in cancer treatment today.”
Greg Siokas, CEO of Cosmos Health, stated: “We are honored to welcome Professor Trafalis, a distinguished oncology leader, to spearhead our research initiatives. His expertise in clinical development will accelerate our efforts to address unmet medical needs and deliver transformative therapies to patients globally. We look forward to his invaluable contributions as we continue to build a robust oncology pipeline.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What is Professor Dimitrios Trafalis’s role at Cosmos Health (COSM)?
Professor Dimitrios Trafalis has been appointed as Head of Oncology at Cosmos Health’s Research and Development division, where he will lead research initiatives, oversee preclinical and clinical protocols, and present developments at global medical conferences.
How will Professor Trafalis’s appointment impact COSM’s oncology research?
His appointment will strengthen the company’s research initiatives, focusing on preclinical and clinical development strategies, regulatory support, and cutting-edge studies in oncology.
What experience does Professor Trafalis bring to Cosmos Health (COSM)?
Professor Trafalis brings expertise in oncology-hematology, cancer cytogenetics, personalized cancer therapies, and clinical pharmacology, along with extensive research experience and multiple scientific publications.
What are the main objectives of COSM’s oncology research under Professor Trafalis?
The main objectives include advancing groundbreaking therapeutics in oncology, developing clinical strategies for cancer treatment, and delivering transformative therapies to patients globally.
